Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
University of Miami
M.D. Anderson Cancer Center
Brown University
Memorial Sloan Kettering Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Incyte Corporation
Incyte Corporation
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
University of Nebraska
Northwestern University
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Fred Hutchinson Cancer Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Karyopharm Therapeutics Inc
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
OHSU Knight Cancer Institute
Beth Israel Deaconess Medical Center
Washington University School of Medicine
University of Nebraska
University of Nebraska
Dartmouth-Hitchcock Medical Center
University of Birmingham
Masonic Cancer Center, University of Minnesota
Melbourne Health
Rutgers, The State University of New Jersey
Northside Hospital, Inc.
Amgen
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
University of Virginia
Scripps Health
Prelude Therapeutics